Bioventix Plc Issue of Equity

 
TIDMBVXP 
 
Bioventix plc 
 
                        ("Bioventix" or "the Company") 
 
                                Issue of Equity 
 
Bioventix plc (BVXP) a UK company specialising in the development and 
commercial supply of high-affinity monoclonal antibodies for applications in 
clinical diagnostics, announces that it has applied for 40,018 ordinary shares 
of 5 pence each (the "Option Shares") to be admitted to trading on AIM 
("Admission"). It is expected that Admission will occur and that dealings will 
commence in the Option Shares on 5 April 2017. 
 
The Option Shares are being issued pursuant to the exercise of options by 
employees of the Company. The Option Shares will rank pari passu with the 
existing ordinary shares of 5 pence each in the capital of the Company 
("Ordinary Shares"). 
 
The total number of Ordinary Shares in issue following Admission will be 
5,138,674 and the Company holds no shares in treasury. Therefore the total 
number of Ordinary Shares with voting rights in the Company will be 5,138,674. 
 
The above figure of 5,138,674 may be used by shareholders as the denominator 
for the calculations by which they will determine if they are required to 
notify their interest in, or a change to their interest in, Bioventix under the 
FCA's Disclosure and Transparency Rules. 
 
For further information please contact: 
 
Bioventix plc                                     Tel: 01252 728 001 
Peter Harrison           Chief Executive Officer 
 
finnCap Ltd                                       Tel: 020 7220 0500 
Geoff Nash/Simon Hicks   Corporate Finance 
Stephen Norcross         Corporate Broking 
 
About Bioventix plc: 
 
Bioventix (www.bioventix.com) specialises in the development and commercial 
supply of high-affinity monoclonal antibodies with a primary focus on their 
application in clinical diagnostics, such as in automated immunoassays used in 
blood testing. The antibodies created at Bioventix are generated in sheep and 
are of particular benefit where the target is present at low concentration and 
where conventional monoclonal or polyclonal antibodies have failed to produce a 
suitable reagent. Bioventix currently offers a portfolio of antibodies to 
customers for both commercial use and R&D purposes, for the diagnosis or 
monitoring of a broad range of conditions, including heart disease, cancer, 
fertility, thyroid function and drug abuse. Bioventix currently supplies 
antibody products and services to the majority of multinational clinical 
diagnostics companies. Bioventix is based in Farnham, UK and its shares are 
traded on AIM under the symbol BVXP. 
 
The information communicated in this announcement contains inside information 
for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014. 
 
 
 
END

(END) Dow Jones Newswires

March 30, 2017 06:21 ET (10:21 GMT)

Bioventix (AQSE:BVXP.GB)
Historical Stock Chart
From Jan 2025 to Feb 2025